Your browser doesn't support javascript.
loading
Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder.
Laffont, Celine M; Ngaimisi, Eliford; Gopalakrishnan, Mathangi; Ivaturi, Vijay; Young, Malcolm; Greenwald, Mark K; Heidbreder, Christian.
Affiliation
  • Laffont CM; Indivior Inc., North Chesterfield, VA, United States.
  • Ngaimisi E; Center for Translational Medicine, University of Maryland, Baltimore, MD, United States.
  • Gopalakrishnan M; Center for Translational Medicine, University of Maryland, Baltimore, MD, United States.
  • Ivaturi V; Center for Translational Medicine, University of Maryland, Baltimore, MD, United States.
  • Young M; Indivior Inc., North Chesterfield, VA, United States.
  • Greenwald MK; Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, MI, United States.
  • Heidbreder C; Indivior Inc., North Chesterfield, VA, United States.
Front Pharmacol ; 13: 1052113, 2022.
Article in En | MEDLINE | ID: mdl-36467036
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies Aspects: Equity_inequality Language: En Journal: Front Pharmacol Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials / Prognostic_studies Aspects: Equity_inequality Language: En Journal: Front Pharmacol Year: 2022 Document type: Article Affiliation country: Country of publication: